A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the combination of pemetrexed and gefitinib versus
gefitinib alone, in terms of progression-free survival. This study is in participants who
have stage IV non squamous NSCLC with activating epidermal growth factor mutations and who
have not had any previous chemotherapy for stage IV disease.